4PTE

Structure of a carvoxamide compound (15) (N-[4-(ISOQUINOLIN-7-YL)PYRIDIN-2-YL]CYCLOPROPANECARBOXAMIDE) to GSK3b


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.033 Å
  • R-Value Free: 0.195 
  • R-Value Work: 0.169 

wwPDB Validation 3D Report Full Report


This is version 1.1 of the entry. See complete history

Literature

Discovery of new acylaminopyridines as GSK-3 inhibitors by a structure guided in-depth exploration of chemical space around a pyrrolopyridinone core.

Sivaprakasam, P.Han, X.Civiello, R.L.Jacutin-Porte, S.Kish, K.Pokross, M.Lewis, H.A.Ahmed, N.Szapiel, N.Newitt, J.A.Baldwin, E.T.Xiao, H.Krause, C.M.Park, H.Nophsker, M.Lippy, J.S.Burton, C.R.Langley, D.R.Macor, J.E.Dubowchik, G.M.

(2015) Bioorg.Med.Chem.Lett. 25: 1856-1863

  • DOI: 10.1016/j.bmcl.2015.03.046
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 
  • Glycogen synthase kinase-3 (GSK-3) has been proposed to play a crucial role in the pathogenesis of many diseases including cancer, stroke, bipolar disorders, diabetes and neurodegenerative diseases. GSK-3 inhibition has been a major area of pharmaceu ...

    Glycogen synthase kinase-3 (GSK-3) has been proposed to play a crucial role in the pathogenesis of many diseases including cancer, stroke, bipolar disorders, diabetes and neurodegenerative diseases. GSK-3 inhibition has been a major area of pharmaceutical interest over the last two decades. A plethora of reports appeared recently on selective inhibitors and their co-crystal structures in GSK-3β. We identified several series of promising new GSK-3β inhibitors from a coherent design around a pyrrolopyridinone core structure. A systematic exploration of the chemical space around the central spacer led to potent single digit and sub-nanomolar GSK-3β inhibitors. When dosed orally in a transgenic mouse model of Alzheimer's disease (AD), an exemplary compound showed significant lowering of Tau phosphorylation at one of the GSK-3 phosphorylating sites, Ser396. X-ray crystallography greatly aided in validating the binding hypotheses.


    Organizational Affiliation

    Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA. Electronic address: prasanna.siva@bms.com.,Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA. Electronic address: xiaojun.han@bms.com.,Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA.,Bristol-Myers Squibb Research and Development, PO Box 4000, Princeton, NJ 08543, USA.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Glycogen synthase kinase-3 beta
A, B
441Homo sapiensMutation(s): 0 
Gene Names: GSK3B
EC: 2.7.11.26
Find proteins for P49841 (Homo sapiens)
Go to Gene View: GSK3B
Go to UniProtKB:  P49841
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
2WF
Query on 2WF

Download SDF File 
Download CCD File 
A, B
N-[4-(isoquinolin-7-yl)pyridin-2-yl]cyclopropanecarboxamide
C18 H15 N3 O
PGKFRHOTYGEBDX-UHFFFAOYSA-N
 Ligand Interaction
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
2WFIC50: 74 nM (100) BINDINGDB
2WFIC50: 74 nM BINDINGMOAD
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.033 Å
  • R-Value Free: 0.195 
  • R-Value Work: 0.169 
  • Space Group: P 21 21 21
Unit Cell:
Length (Å)Angle (°)
a = 81.642α = 90.00
b = 83.514β = 90.00
c = 178.238γ = 90.00
Software Package:
Software NamePurpose
PHENIXrefinement

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

Revision History 

  • Version 1.0: 2015-04-08
    Type: Initial release
  • Version 1.1: 2015-06-10
    Type: Database references